Metachronous PDAC after breast cancer is a rare but serious occurrence, typically linked to hereditary predisposition syndromes involving pathogenic variants in homologous recombination repair (HRR) genes such as BRCA2, PALB2, and ATM (3–5). The gene discussed is BRCA2; the disease is breast carcinoma.